Drug intelligence / Profile preview

PNA-TO-MB

Development stage
Preclinical
Lead developer
Hebrew University of Jerusalem
Modality
Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Peptides
01

Overview

PNA-TO-MB is a peptide nucleic acid (PNA)-based molecular beacon (MB) conjugated with the fluorophore thiazole orange (TO). Developed as a diagnostic tool for the early detection of gastrointestinal malignancies, it specifically targets mutations in the K-ras oncogene, such as the codon 12 GGT→GAT mutation. The PNA backbone provides a neutral charge and high binding affinity, allowing for faster hybridization kinetics and superior sequence specificity compared to traditional DNA-based probes. Thiazole orange serves as a light-up fluorescent reporter, exhibiting a significant increase in fluorescence upon hybridization to the target mRNA transcript, which facilitates the identification of malignant and pre-malignant lesions in fixed cells and total RNA samples.

Other names
peptide nucleic acid molecular beaconPNA molecular beacon
02

Targets

Kirsten rat sarcoma viral oncogene homolog mRNAKRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on PNA-TO-MB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNA-TO-MB.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call